Samsung Biologics

207940, KOSPI, Healthcare

₩1,201,000▼ ₩18,042-1.48%2026-10-12 close

Prev. close: ₩1,219,042
Volume: 60.9K
Market cap: ₩55.6T

-40% from high

Stock and sector context

Healthcareoutflow

Sector comparison: Of 13 covered Healthcare stocks in Korean, 12 fell; the average change was -3.35%. Samsung Biologics moved in the same direction at -1.48%. Estimated sector flow was outflow.
Variables to watch: Drug approvals and trial resultsDrug pricing policyUS interest ratesUSD/KRW
Risks to check: -40% below the high, the downtrend may continue
Clinical trial failure
Drug pricing pressure

This compares price changes among covered stocks in the same market. It does not establish why prices moved. Variables and risks are sector reference lists.

Why a candidate

Match 52/100

The match score marks how many conditions overlap on a 0 to 100 scale: the 52-week range, valuation metrics, price change and volume. It is not a probability of rising or a forecast return.

vs 52w high -40%Oversold

Today's read

Samsung Biologics scores 52 out of 100 on today's InverseOne match ranking, 29 of 60 in the Korean large-cap universe. The gap to its 52-week high is 65%. Today's move of -1.48% came with money flowing out; the broader Healthcare sector flow is worth checking. Scores are estimates built from price and volume, a starting point for research rather than a trading signal.

Data basis: 2026-10-12 close, 10-14 00:20 KST updated, For reference only, not advice

Same-sector stocks, Healthcare

Lending balance

Little change

680,405 sh

KRW 0.82T

1D +0.11%5D +0.56%

New 52,687 sh, Returned 51,925 sh

Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.

As of 2026-10-12, FSC stock lending data

Company profile

Unqualified opinion

삼성바이오로직스(주)

CEO: 임존종보 (Rim John Chongbo)
Employees: 5,455
Average tenure: 5.3 years
Average pay per employee: ₩114M
Listed: 2016-11-10
Founded: 2011-04-22
Auditor: 삼정회계법인

As filed 2026-10-12

Company site

Talk about this stock

New thread

Today's talking points

It sits low in its 52-week range (20).
It is 65% below its 52-week high.

Three months out, which way do you see it?

Nobody has answered yet. Sign in to be the first.

These are answers picked by members, not investment advice.

Fund-flow signal

Outflow index-₩1.1B

Net flow, Outflow

Market flow rank: Outflow #30 of 52
Sector flow rank: #10 of 13

Trend building (not enough trading days)

Market data

52-week range: ₩1,003,000 ~ ₩1,987,000

52-week position20/100

₩1,003,000₩1,987,000

Gap to 52w high+65.4%

AI zone read

Worth watchingCondition score 64

Evidence

Near the low20
Gap to the high65.4
How firm the news is2.4

This formula has not passed after-the-fact validation yet. Its results are being collected on the record page.

AI reads the headlines; the zone comes from a published formula.

See the formula

Same-sector stocks

Sam Chun Dang Pharm000250, Healthcare-12.73%LigaChem Biosciences141080, Healthcare-5.73%ST Pharm237690, Healthcare-4.20%ALTEOGEN196170, Healthcare-3.94%Lunit328130, Healthcare-3.34%HLB028300, Healthcare-2.74%CLASSYS214150, Healthcare-2.64%HK inno.N195940, Healthcare-2.52%

These figures are reference estimates built from price and volume: a starting point for narrowing down ideas, not a buy or sell signal.